Evgen Pharma Plc (EVG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Evgen Pharma Plc (EVG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8129
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company that develops clinical pipeline for breast cancer and subarachnoid haemorrhage. The company develops SFX-01 to reduce the vasospasm and incidence of delayed cerebral ischemia which leads to cognitive impairment. Its clinical pipeline product is based on proprietary Sulforadex platform technology that synthesizes and concurrently stabilizes the naturally occurring compound such as sulforaphane. Evgen Pharma carries out preclinical work in multiple sclerosis and has clinical interest in prostate cancer. The company also conducts clinical trials in oncology in patients with ER+ metastatic breast cancer. It has operations in Wilmslow, Liverpool and London, the UK. Evgen Pharma is headquartered in Wilmslow, the UK.

Evgen Pharma Plc (EVG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Evgen Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Evgen Pharma Raises USD3.1 Million Financing 10
Evgen Raises US$0.72 Million In Series B Financing 11
Partnerships 12
Evgen Pharma Enters into Agreement with Imperial College London 12
Evgen Pharma Enters into Agreement with King’s College London 13
Licensing Agreements 14
Evgen Pharma Exercises Option for Licensing Agreement with CSIC and University of Seville 14
Equity Offering 15
Evgen Pharma Raises USD1 Million in Private Placement of Shares 15
Evgen Pharma Raises USD11 Million in IPO 16
Evgen Pharma Plc – Key Competitors 17
Evgen Pharma Plc – Key Employees 18
Evgen Pharma Plc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Jun 13, 2018: Evgen Pharma: Final Results for the year ended 31 March 2018 20
Dec 08, 2017: Evgen Pharma: Interim results for the six months ended 30 September 2017 21
Jun 13, 2017: Evgen Pharma Announces Final Results for the year ended 31 March 2017 22
Corporate Communications 23
Apr 03, 2017: Evgen Pharma Announces Directorate Change 23
Jan 17, 2017: Evgen Pharma: Appointment of CFO and Head of Clinical Operations 24
Product News 25
08/02/2017: Evgen Pharma: SFX-01 data published in Peer Reviewed Journal 25
Clinical Trials 26
Jun 11, 2018: Evgen Pharma: Interim update on STEM trial 26
Apr 24, 2018: Evgen Pharma Announces Presentation at World Orphan Drug Congress USA 28
Mar 05, 2018: Evgen Pharma: Update on novel sulforaphane analogues 29
Jan 15, 2018: Evgen Pharma: Poster presentation of SFX-01 stem cell data in breast cancer 30
Dec 11, 2017: Hardman Research: Funded to the end of Phase II trials 31
Oct 04, 2017: Evgen Pharma: First European Patent Grant 32
Jul 11, 2017: Evgen Pharma: Charity-funded Study of SFX-01 in Triple Negative Breast Cancer 33
Jan 17, 2017: Evgen Pharma Announces First Patient Dosed in Phase II Breast Cancer Trial 34
Jan 11, 2017: Evgen Pharma Receives Positive DSMB Review of SAS Trial 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Evgen Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Evgen Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Evgen Pharma Raises USD3.1 Million Financing 10
Evgen Raises US$0.72 Million In Series B Financing 11
Evgen Pharma Enters into Agreement with Imperial College London 12
Evgen Pharma Enters into Agreement with King's College London 13
Evgen Pharma Exercises Option for Licensing Agreement with CSIC and University of Seville 14
Evgen Pharma Raises USD1 Million in Private Placement of Shares 15
Evgen Pharma Raises USD11 Million in IPO 16
Evgen Pharma Plc, Key Competitors 17
Evgen Pharma Plc, Key Employees 18
Evgen Pharma Plc, Other Locations 19

List of Figures
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Evgen Pharma Plc (EVG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Origin Energy Limited:戦略・SWOT・企業財務分析
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tupperware Brands Corp (TUP):企業の財務・戦略的SWOT分析
    Tupperware Brands Corp (TUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cobb Electric Membership Corporation:企業の戦略的SWOT分析
    Cobb Electric Membership Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Response Biomedical Corp:企業の戦略的SWOT分析
    Response Biomedical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Ajinomoto Co Inc (2802):製薬・医療:M&Aディール及び事業提携情報
    Summary Ajinomoto Co Inc (Ajinomoto) is a food products company that focuses on foods, bioscience fine chemicals and pharmaceuticals and health. It carries out research and development and production of seasonings, and provides Knorr cup soup products, processed foods, edible oils, sweeteners, bever …
  • Anchor Glass Container Corp.:企業の戦略・SWOT・財務情報
    Anchor Glass Container Corp. - Strategy, SWOT and Corporate Finance Report Summary Anchor Glass Container Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Chorus Aviation Inc.:戦略・SWOT・企業財務分析
    Chorus Aviation Inc. - Strategy, SWOT and Corporate Finance Report Summary Chorus Aviation Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Selex Gruppo Commerciale S.p.A.:戦略・SWOT・企業財務分析
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Shinsegae Food Co., Ltd.:企業の戦略・SWOT・財務情報
    Shinsegae Food Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shinsegae Food Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Nagacorp Ltd:企業の戦略・SWOT・財務情報
    Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • United Bank of India:企業の戦略・SWOT・財務情報
    United Bank of India - Strategy, SWOT and Corporate Finance Report Summary United Bank of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • TransUnion LLC:企業の戦略・SWOT・財務分析
    TransUnion LLC - Strategy, SWOT and Corporate Finance Report Summary TransUnion LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • China National Offshore Oil Corp:企業の戦略的SWOT分析
    China National Offshore Oil Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Gol Linhas Aereas Inteligentes SA :企業の戦略・SWOT・財務情報
    Gol Linhas Aereas Inteligentes SA - Strategy, SWOT and Corporate Finance Report Summary Gol Linhas Aereas Inteligentes SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • The Broad Institute Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up th …
  • Restalia Grupo de Eurorestauracion SL:企業の戦略・SWOT・財務分析
    Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report Summary Restalia Grupo de Eurorestauracion SL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • RCS MediaGroup SpA (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup SpA (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Humanigen Inc (HGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodi …
  • Co-Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆